The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Baseline TP53 mutations in Adults with SCD developing Myeloid Malignancy following Hematopoietic Cell Transplantation
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This may also be relevant to other transplantation settings as blood cancers have also been reported in patients with SCD treated with HCT48–54.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [49]
In the citing paper
“However, one early BB305 trial in SCD was associated with the development of myelodysplastic syndrome/acute myeloid leukemia in two recipients.88,89”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Bone-Marrow Transplantation in a Patient with Sickle-Cell Anemia
Johnson, F. L., Look, A. T., Gockerman, J., Ruggiero, M. R., Dalla-Pozza, L., & Billings, F. T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409203111207 · Cited by 321
Research works printed but not linked: 18
- Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17): 3447-3452.
- Brunson A, Keegan THM, Bang H, Mahajan A, Paulukonis S, Wun T. Increased risk of leukemia among sickle cell disease patients in California. Blood. 2017;130(13):1597-1599.
- Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ. Risk of individ- ual malignant neoplasms in patients with sickle cell disease: English national record linkage study. J R Soc Med. 2016;109(8): 303-309.
- Aumont C, Driss F, Lazure T, et al. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol. 2015;90(7):E131-E132.
- Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F. Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol. 2012;6:149-152.
- Taylor JG, Darbari DS, Maric I, McIver Z, Arthur DC. Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia. Ann Intern Med. 2011;155(10):722-724.
- Regan S, Yang X, Finnberg NK, El-Deiry WS, Pu JJ. Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient. Cancer Biol Ther. 2019;20(11):1389-1397.
- Li Y, Maule J, Neff JL, et al. Myeloid neoplasms in the setting of sickle cell disease: an intrinsic association with the underlying condition rather than a coincidence; report of 4 cases and review of the literature. Mod Pathol. 2019;32(12):1712-1726.
- Schultz WH, Ware RE. Malignancy in patients with sickle cell disease. Am J Hematol. 2003;74(4):249-253.
- Stricker RB, Linker CA, Crowley TJ, Embury SH. Hematologic malignancy in sickle cell disease: report of four cases and review of the literature. Am J Hematol. 1986;21(2):223-230.
- Samal GC. Sickle cell anemia with acute myeloid leukemia-(a case report). Indian Pediatr. 1979;16(5):453-454.
- Goldin AG, Kelty KC, Beard MF. Sickle cell anemia terminating in acute myeloblastic leukemia. Ann Intern Med. 1953;39(4):920-928.
- Zemenides S, Erblich T, Luqmani A, Bain BJ. Peripheral blood features of acute myeloid leukemia with myelodysplasia-related changes de- veloping in a patient with sickle cell anemia. Am J Hematol. 2014;89(10): 1010.
- Fitzhugh CD, Hsieh MM, Taylor T, et al. Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. Blood Adv. 2017;1(11):652-661.
- Janakiram M, Verma A, Wang Y, et al. Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leuk Lymphoma. 2018;59(1):241-244.
- Castro O, Nouraie M, Oneal P. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol. 2014;167(5):687-691.
- McGann PT, Flanagan JM, Howard TA, et al; BABY HUG Investigators. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer. 2012;59(2):254-257.
- Maia Filho PA, Pereira JF, Almeida Filho TP, Cavalcanti BC, Sousa JC, Lemes RPG. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environ Mol Mutagen. 2019;60(3):302-304.
Cited by
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 67
The p53 challenge of hematopoietic stem cell gene editing
Dorset, S. R., & Bak, R. O. (2023) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2023.06.003 · Cited by 33
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Metadata
- Authors
- Ghannam, J. Y., Xu, X., Maric, I., Dillon, L., Li, Y., Hsieh, M., Hourigan, C. S., & Fitzhugh, C. D.
- Affiliations
- National Heart, Lung and Blood Institute, Bethesda, Maryland, United States
- NHLBI, NIH, Bethesda, Maryland, United States
- CC/NIH, Bethesda, Maryland, United States
- National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
- NIH, Bethesda, Maryland, United States
- National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-02-14
- ISSN
- 0006-4971
- 1528-0020
- Cited by
- 8
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
